Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK seeks bids for 4...

    GSK seeks bids for 4 billion dollar India sale by mid-Sept: Report

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-08-24T09:30:35+05:30  |  Updated On 24 Aug 2018 9:30 AM IST
    GSK seeks bids for 4 billion dollar India sale by mid-Sept: Report

    UK pharmaceutical giant GSK has requested bids by mid-September for its $4.3-billion Indian consumer-health unit, which owns the popular malted milk brand Horlicks, people with knowledge of the matter said.


    GSK has sent out an information memorandum with preliminary details about the business to potential suitors, according to the people, who asked not to be identified because the information is private. The sale has attracted interest from potential bidders including Nestle, PepsiCo and Reckitt Benckiser Group, they said.


    The UK drugmaker announced in March that it aims to complete a strategic review of Horlicks and other nutritional products by the end of this year. The company is assessing its 72.5% holding in India-listed GSK Consumer Healthcare as part of that process.


    Proceeds from a potential sale could be used to finance GSK's $13-billion buyout of Novartis' stake in their consumer-health joint venture. Representatives for Glaxo and Nestle declined to comment. Spokesmen for Reckitt and Pepsi had no immediate comment.


    GSK's review of assets includes its 82% stake in the Dhaka-listed GSK Bangladesh, as well as marketing rights to some consumer-health brands in other emerging economies, the people said. There's no certainty the deliberations will lead to a transaction, and the parent company may yet decide to keep the businesses, they said. Shares of GSK Consumer Healthcare have advanced almost 10% in Mumbai trading this year, giving it a market value of Rs 29,900 crore ($4.3 billion).

    GSKGSK Consumer HealthcareHorlicksNestleNovartisPepsiCopharmaReckitt BenckiserUK
    Source : Bloomberg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok